Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.STLN · Entity 5327 | Director | August 21, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 411,976 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Sale · Disposed 298,853 · Balance 411,976 F1: Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 24, 2026 21:11 UTC | Starling Oncology, Inc. STLN · Entity 5327 | SaleCommon Stock | 298,853 | $6.51 | $1,946,310.05 |
DisclosureSEC source: 0001079973-26-001175 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 411,976 F1 · price: Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 22:49 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 27,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000983 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,829 F1 · kind: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 13,333 | $3.77 | $50,290.74 |
DisclosureSEC source: 0001079973-25-001861 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 683,721 F1 · kind: The reporting person used the proceeds of this sale to cover tax liabilities arising from the vesting of an RSU award on November 20, 2025. F2 · price: Price of $3.771921 was the volume weighted average selling price of all sales by the reporting person on December 15, 2025 within a one-dollar range. Actual prices ranged from $3.770 to $3.785. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:20 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 32,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000143 · ownership.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,054 F2 · shares: Represents restricted stock units that were fully vested upon grant. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:20 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 41,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001553350-25-000143 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 664,647 F1 · shares: Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 19:13 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 20,221 | $4.06 | $82,097.26 |
DisclosureSEC source: 0000935836-25-000552 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,980 Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 946,460 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · derivative · entry 10 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 946,460 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options vested monthly for 48 months following December 2, 2019. F6 · balance_after: Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 131,297 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · derivative · entry 9 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,297 shares Expires 2032-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options vested monthly starting November 17, 2022, with cancellation of remaining options pursuant to Note 6 below. F6 · balance_after: Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 105,320 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · derivative · entry 8 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,320 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options vested monthly starting March 17, 2023, with cancellation of remaining options pursuant to Note 6 below. F6 · balance_after: Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 684,528 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · derivative · entry 7 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 684,528 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options vested monthly for 36 months following November 12, 2021. F6 · balance_after: Pursuant to a Transition Agreement with the Reporting Person, all unvested options were cancelled after June 30, 2024. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 108,532 | $2.87 | $311,519.40 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 6 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,501 F1 · security: Represents sale of Common Stock acquired from previously vested RSU awards. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 1,867,605 | $2.87 | $5,360,586.63 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 5 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,033 Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon Stock | 946,460 | $0.85 | $804,491.00 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 4 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,579,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon Stock | 131,297 | $1.87 | $245,525.39 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 3 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,633,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon Stock | 105,320 | $0.48 | $50,658.92 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,501,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 22:51 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon Stock | 684,528 | $0.85 | $581,848.80 |
DisclosureSEC source: 0000935836-25-000416 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,396,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Warrant · Derivative | 4,528 | $0.13 Strike: $1.20 | $566.00 |
DisclosureSEC source: 0001079973-25-000521 · ownership.xml · derivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 4,528 shares Expires 2030-03-26 F1 · security: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. F4 · derivative.exercise_date: The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 9,056 | $1.04 | $9,433.64 |
DisclosureSEC source: 0001079973-25-000521 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,809 F1 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. Read SEC document |
| March 26, 2025 Filed Apr 28, 2025 23:20 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Warrant · Derivative | 22,640 | $0.13 Strike: $1.20 | $2,830.00 |
DisclosureSEC source: 0000935836-25-000296 · ownership.xml · derivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,640 Underlying: Common Stock · 22,640 shares Expires 2030-03-26 F2 · security: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F2 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F3 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F1 · shares: This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected. F4 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. F5 · derivative.exercise_date: The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act. F1 · derivative.underlying_shares: This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected. Read SEC document |
| March 26, 2025 Filed Apr 28, 2025 23:20 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 45,280 | $1.04 | $47,168.18 |
DisclosureSEC source: 0000935836-25-000296 · ownership.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,033 F2 · kind: Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). F3 · kind: The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F1 · shares: This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected. F4 · price: Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 21:04 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon stock | 50,000 | $0.15 | $7,500.00 |
DisclosureSEC source: 0001799191-24-000063 · wk-form4_1733173486.xml · nonDerivative · entry 3 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 666,753 F2 · balance_after: 44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date. Read SEC document |
| November 26, 2024 Filed Dec 2, 2024 21:04 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon stock | 250,000 | $0.17 | $42,500.00 |
DisclosureSEC source: 0001799191-24-000063 · wk-form4_1733173486.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 616,753 F2 · balance_after: 44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:14 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-24-000050 · wk-form4_1732569282.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,203 F1 · shares: Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| November 12, 2024 Filed Dec 2, 2024 21:04 UTC | Starling Oncology, Inc. TOI · Entity 5327 | OtherCommon stock | 353,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-24-000063 · wk-form4_1733173486.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,753 F1 · balance_after: Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 and $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:17 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 18,121 | $0.46 | $8,295.79 |
DisclosureSEC source: 0001799191-24-000015 · edgardoc.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,203 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:22 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 19,526 | $0.58 | $11,233.31 |
DisclosureSEC source: 0001799191-24-000013 · edgardoc.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 694,324 F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:46 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 42,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-042829 · wk-form4_1703803565.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713,850 F1 · price: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 02:01 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon stock | 25,867 | $2.19 | $56,726.33 |
DisclosureSEC source: 0001628280-23-039913 · wk-form4_1700704878.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671,198 Read SEC document |
| November 17, 2023 Filed Nov 22, 2023 00:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001628280-23-039815 · wk-form4_1700612843.xml · derivative · entry 3 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,745,431 Underlying: Common stock · 25,000 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination. Read SEC document |
| November 17, 2023 Filed Nov 22, 2023 00:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 25,000 | $2.24 | $56,000.00 |
DisclosureSEC source: 0001628280-23-039815 · wk-form4_1700612843.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,065 Read SEC document |
| November 17, 2023 Filed Nov 22, 2023 00:27 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon stock | 25,000 | $0.85 | $21,250.00 |
DisclosureSEC source: 0001628280-23-039815 · wk-form4_1700612843.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 23:49 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon stock | 27,117 | $2.39 | $64,755.40 |
DisclosureSEC source: 0001628280-23-039192 · wk-form4_1700092157.xml · nonDerivative · entry 3 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,065 Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 23:49 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001628280-23-039192 · wk-form4_1700092157.xml · derivative · entry 4 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770,431 Underlying: Common stock · 47,000 shares Expires 2029-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of December 2, 2019 (the "Original Grant Date"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 23:49 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 47,000 | $2.52 | $118,581.00 |
DisclosureSEC source: 0001628280-23-039192 · wk-form4_1700092157.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,182 Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 23:49 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Exercise / conversionCommon stock | 47,000 | $0.85 | $39,950.00 |
DisclosureSEC source: 0001628280-23-039192 · wk-form4_1700092157.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 771,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:44 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 421,280 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001628280-23-008825 · wf-form4_167944585635107.xml · derivative · entry 2 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,280 Underlying: Common stock · 421,280 shares Expires 2033-03-17 F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:44 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 168,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008825 · wf-form4_167944585635107.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,182 F1 · shares: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 525,188 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001799191-22-000032 · edgardoc.xml · derivative · entry 2 Hively Brad · CIK 0001891124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,188 Underlying: Common Stock · 525,188 shares Expires 2032-11-17 F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:31 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 103,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000032 · edgardoc.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,670 F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 9,718 | $2.03 | $19,706.16 |
DisclosureSEC source: 0001799191-22-000012 · edgardoc.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,201 F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 23, 2022 01:07 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 9,718 | $2.03 | $19,706.16 |
DisclosureSEC source: 0001799191-22-000050 · edgardoc.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,201 F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:36 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 88,090 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007101 · wf-form4_164807859777265.xml · derivative · entry 2 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,090 Underlying: Common stock · 88,090 shares Expires 2032-03-21 F3 · derivative.exercise_date: The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:36 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 108,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007101 · wf-form4_164807859777265.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,919 F1 · shares: Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F1 · price: Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F2 · balance_after: The reporting person's last filing incorrectly reported 363,450 total holdings instead of 353,450 total holdings. Read SEC document |
| March 21, 2022 Filed Mar 30, 2022 00:10 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 550,563 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007759 · wf-form4a_164859901030434.xml · derivative · entry 1 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,563 Underlying: Common stock · 550,563 shares Expires 2032-03-21 F1 · derivative.exercise_date: The stock options vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:53 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Options (right to buy) · Derivative | 823,971 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001104659-21-140219 · tm2132979-10_4seq1.xml · derivative · entry 4 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 823,971 shares Expires 2029-12-02 F5 · kind: These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date. F5 · derivative.exercise_date: These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:53 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Options (right to buy) · Derivative | 993,460 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001104659-21-140219 · tm2132979-10_4seq1.xml · derivative · entry 3 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 993,460 shares Expires 2029-12-02 F4 · kind: These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the "Original Grant Date"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. F4 · derivative.exercise_date: These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocable share of stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the "Original Grant Date"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. Read SEC document |
| November 12, 2021 Filed Nov 19, 2021 01:25 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 212,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-141460 · tm2133425-3_4aseq1.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,450 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger ("Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F3 · acquired: The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
| November 12, 2021 Filed Nov 19, 2021 01:25 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 141,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-141460 · tm2133425-3_4aseq1.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,380 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger ("Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acquisitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surviving corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F2 · acquired: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
| January 12, 2021 Filed Nov 17, 2021 02:53 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 212,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-140219 · tm2132979-10_4seq1.xml · nonDerivative · entry 2 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,070 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger ("Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F3 · acquired: The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
| January 12, 2021 Filed Nov 17, 2021 02:53 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 141,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-140219 · tm2132979-10_4seq1.xml · nonDerivative · entry 1 Hively Brad · CIK 0001891124 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,380 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger ("Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F2 · acquired: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.